Contract Research Organizations (CROs) and Research Company
Type of Data
Patient Health Data, Clinical Trial Data
Summary of Pain Point
No Real-Time data analysis
Blinded studies, in general, prohibit interim analysis
Global trials are subject to different privacy laws
Expensive and time consuming to move and combine data in a centralized location for continuous real-time analysis before study completion
Could miss critical pieces of information if granular patient-level data is not part of the aggregation process
Data needs to be de-identified before publications/analysis
Summary of TripleBlind’s Solution
The “Lot Control Numbers” can be matched using privacy enhancing computation (“blindly”), and placebo/real attribute can be joined to efficacy attributes.
“Blinding” is never compromised, aggregated data can be used for early indication reporting.
Attributes returned are controlled, query is “permitted” beforehand, and audit trails are created.
Efficacy reporting is available during study progression.
Similar use cases
Book A Demo
TripleBlind’s innovations build on well understood principles of data protection. Our innovations radically improve the practical use of privacy preserving technologies, by adding true scalability and faster processing, with support for all data and algorithm types. We support all cloud platforms and unlock the intellectual property value of data, while preserving privacy and enforcing compliance with HIPAA and GDPR.